Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

Chemotherapy mobilization dosing regimen (control patients).

Perixafor mobilization dosing regimen (EAP study patients).

Total median costs associated with successive days to mobilization. The total cost of mobilization for each patient was determined through the indicated day of apheresis and medians were calcultaed for each group in each day of apheresis. The upper boundary of the box represents the 75th percentile and the lower boundary the 25th percentile; the line represents the median for each group.